Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic intervention.

Biochemical recurrence after definitive local therapy for prostate cancer represents a heterogeneous clinical state, with patients exhibiting short prostate-specific antigen (PSA) doubling time at particularly high risk of metastatic progression and cancer-related mortality. Persistent androgen receptor signaling plays a central role in sustaining occult micrometastatic disease, providing a strong biological rationale for early therapeutic intervention. The phase III EMBARK trial demonstrated that intensification of androgen receptor pathway inhibition with enzalutamide, administered either in combination with androgen deprivation therapy or as monotherapy, significantly improves metastasis-free survival and delays disease progression in patients with high-risk biochemical recurrence, with an overall survival benefit observed for combination therapy. Importantly, EMBARK introduced a PSA-guided treatment-suspension strategy designed to reduce cumulative treatment exposure. These findings redefine high-risk biochemical recurrence as an actionable disease state and support the integration of enzalutamide-based approaches into contemporary prostate cancer treatment algorithms.